
Glow Skin 112mg
Glow Skin 112mg is a lyophilized peptide blend combining GHK-Cu (CAS 89030-95-5), a copper-binding tripeptide, with BPC-157 (CAS 137525-51-0) and TB-500 (CAS 885340-08-9), supplied in a pen kit strictly for laboratory and in-vitro research into skin-cell and tissue-repair signalling pathways. Exact per-component ratios should be confirmed against the batch Certificate of Analysis.
£120.00 – £6000.00
Pens
Size
Form: Pen Kit
Quantity
Form: Pen Kit
Pack Size: 112mg
Storage & Handling
Storage (Lyophilized): Store at -20°C in a dry, desiccated environment. – After Reconstitution: Store reconstituted peptide at 2–8°C and use within 30 days. For long-term storage, aliquot and freeze at -20°C. Avoid repeated freeze-thaw cycles. – Reconstitution: Reconstitute in sterile bacteriostatic water or appropriate buffer depending on experimental needs.
â ï¸ This product is sold strictly for in vitro research and laboratory use only. It is not for human or veterinary use. By purchasing or using this product, the buyer agrees they have read, understood and accept the Terms & Conditions of Synedica UK. Terms & Conditions.
"Glow" blends combining a copper tripeptide with two repair-pathway peptides are a widely recognised category across the research-chemical market, and listings for them vary considerably in how precisely they document what is actually in the vial. Many list only a total milligram figure without breaking down the individual components, or repeat a generic "proprietary blend" description without naming the peptides at all. Glow Skin 112mg combines GHK-Cu, BPC-157, and TB-500 — three structurally distinct peptides studied, separately, in dermatological and tissue-repair research literature. This page sets out what each component is, what the published research on each has found, and what to check before assuming a listing's blend ratio matches what is actually in a given batch.
What GHK-Cu, BPC-157 and TB-500 Are
GHK-Cu is a copper-binding tripeptide (glycyl-L-histidyl-L-lysine complexed with a copper ion), naturally occurring in human plasma at low concentration and studied for its role in fibroblast signalling and extracellular-matrix remodelling. It carries CAS number 89030-95-5, molecular formula C14H22CuN6O4, and a molecular weight of approximately 401.9 g/mol.
BPC-157 is a synthetic 15-amino-acid peptide derived from a partial sequence identified in human gastric juice protein, studied in preclinical models for its effects on tissue-repair signalling pathways. It carries CAS number 137525-51-0, molecular formula C62H98N16O22, and a molecular weight of approximately 1,419.5 g/mol.
TB-500 is the synthetic, N-acetylated 7-amino-acid fragment (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid protein — commercially sold "TB-500" is this short fragment, not the full protein, a distinction some listings blur. It carries CAS number 885340-08-9, molecular formula C38H68N10O14, and a molecular weight of approximately 889.0 g/mol.
These three peptides act through different mechanisms — copper-dependent fibroblast and collagen signalling for GHK-Cu, and separate tissue-repair pathways under investigation for BPC-157 and TB-500 — which is why they are combined in dermatological and regenerative research contexts rather than being interchangeable with one another.
What Current Research Says
A 2025 peer-reviewed review (Adnan et al., International Journal of Medical Sciences) examined tripeptides in wound healing and skin regeneration and identified GHK-Cu as the most extensively studied of the group, reporting that it "promotes fibroblast proliferation, collagen synthesis, angiogenesis, and ECM remodeling" through copper-dependent mechanisms, and that it reduces inflammatory cytokine signalling (TNF-α, IL-6) in cell-based models. This built on earlier foundational work by Maquart et al. (1988, FEBS Letters), which first reported that the complex stimulated collagen synthesis in cultured skin fibroblasts at picomolar-to-nanomolar concentrations, and a broader 2018 review by Pickart and Margolina (International Journal of Molecular Sciences) covering GHK-Cu's regenerative signalling and gene-expression effects.
BPC-157 and TB-500 have their own separate preclinical research bases. A 2025 systematic review (Vasireddi et al., HSS Journal) examined BPC-157's investigated role in tissue-repair signalling pathways, and a 2026 scoping review (McGuire et al., Applied Sciences) covered current preclinical evidence for both BPC-157 and TB-500 across tissue-repair models.
None of these findings constitute a treatment, cosmetic-efficacy, or health claim for this research-use product; they describe laboratory and preclinical findings for each peptide studied individually, not what a research-use blend sold by Synedica UK does when applied to skin or tissue.
Specifications
| Property | GHK-Cu | BPC-157 | TB-500 |
|---|---|---|---|
| CAS number | 89030-95-5 | 137525-51-0 | 885340-08-9 |
| Molecular formula | C14H22CuN6O4 | C62H98N16O22 | C38H68N10O14 |
| Molecular weight | ≈401.9 g/mol | ≈1,419.5 g/mol | ≈889.0 g/mol |
| Structure | Tripeptide-copper complex | 15-amino-acid synthetic peptide | 7-amino-acid synthetic fragment (Ac-LKKTETQ) |
| UK legal / regulatory status | Not licensed as a medicine under the Human Medicines Regulations 2012 as sold here — supplied strictly for laboratory research | ||
All three CAS numbers and molecular formulas are independently verifiable against public chemical databases such as PubChem. This 112mg pack figure describes the combined total across the three peptides; the exact per-component split is documented on the batch Certificate of Analysis rather than fixed on this listing, since blend ratios are known to vary between suppliers of similarly named products.
Purity, Batch Testing and Certificate of Analysis Standards
Every Glow Skin 112mg pen kit offered for sale is supplied with third-party analytical documentation rather than a single purity percentage repeated across listings. A Certificate of Analysis (COA) for a multi-component blend like this one should confirm the individual milligram amount of each peptide (GHK-Cu, BPC-157, and TB-500), not only the combined 112mg total, along with the analytical method used (typically HPLC or mass spectrometry), the batch or lot number, and the issuing laboratory. "Glow"-style blends are sold at differing component ratios across the market, so researchers should treat a listing that gives only a total milligram figure — with no per-peptide breakdown available on request — as a red flag rather than an oversight. See our contact page to request a Certificate of Analysis for a specific batch.
Sourcing and Verification
Buying a three-component blend like this from a UK-based supplier does not remove the need to verify what arrives. Before ordering, check that the listing states research-use status clearly, that batch documentation is offered rather than promised only "on request," and that each compound's identity (CAS number, molecular formula) is independently verifiable against a source such as PubChem. Because "TB-500" specifically refers to a synthetic 7-amino-acid fragment rather than the full thymosin beta-4 protein, confirming that a supplier's documentation reflects this correctly is a useful additional check. Glow Skin 112mg is offered for sale on this basis, with documentation available per batch. Researchers examining the individual repair-pathway peptides may also find the Synedica BPC-157 & TB-500 Blend relevant, and the full catalogue is browsable on the research products page.
Frequently Asked Questions
What is Glow Skin 112mg used for?
It supplies a blend of GHK-Cu, BPC-157, and TB-500 for laboratory and in-vitro research into skin-cell signalling, fibroblast activity, and tissue-repair pathways. It is not sold for any therapeutic, cosmetic, dietary, or performance use.
What peptides are in the Glow Skin blend?
It combines GHK-Cu (a copper-binding tripeptide), BPC-157 (a 15-amino-acid synthetic peptide), and TB-500 (the synthetic 7-amino-acid Ac-LKKTETQ fragment of thymosin beta-4). The 112mg pack figure is the combined total across all three; the individual milligram split is documented on the batch Certificate of Analysis.
What ratio of GHK-Cu to BPC-157 to TB-500 does this blend use?
The exact per-component ratio is confirmed on the batch Certificate of Analysis rather than fixed on this listing. "Glow"-style blends are formulated at differing ratios across different suppliers, so researchers should request batch-specific documentation rather than assume a figure seen on another listing applies here.
Is TB-500 the same as thymosin beta-4?
No. Commercially available "TB-500" is a synthetic 7-amino-acid fragment (Ac-LKKTETQ) corresponding to residues 17–23 of thymosin beta-4, a much larger 43-amino-acid protein. TB-500 is not the full protein, and listings that use the two names interchangeably are describing different molecules.
Is it legal to buy this peptide blend as a research chemical in the UK?
UK researchers and laboratories can lawfully purchase compounds such as GHK-Cu, BPC-157, and TB-500 when they are supplied and marketed strictly for research or in-vitro use rather than as a medicine or cosmetic product. This product is not licensed under the Human Medicines Regulations 2012 (SI 2012/1916) and has not been assessed by the MHRA for human safety or efficacy under that route, so it must not be purchased for human or veterinary use.
What has research found about GHK-Cu?
A 2025 peer-reviewed review (Adnan et al., Int J Med Sci) identified GHK-Cu as the most studied tripeptide in wound-healing research, reporting effects on fibroblast proliferation, collagen synthesis, and inflammatory signalling in laboratory models. Earlier foundational work (Maquart et al., 1988, FEBS Letters) first reported its effect on collagen synthesis in cultured skin fibroblasts. These are laboratory and preclinical findings, not claims about this research-use product.
What has research found about BPC-157 and TB-500?
BPC-157 and TB-500 each have their own separate preclinical research base examining tissue-repair signalling pathways, including a 2025 systematic review (Vasireddi et al., HSS Journal) and a 2026 scoping review (McGuire et al., Applied Sciences). These describe laboratory and preclinical findings under investigation, not treatment claims for this product.
What does the Certificate of Analysis (COA) show for a blend product?
For a multi-component blend, a COA should confirm the individual milligram amount of each peptide (GHK-Cu, BPC-157, and TB-500), the analytical testing method (typically HPLC or mass spectrometry), the batch number, and the issuing laboratory — not only a single combined total.
How is the CAS number used to verify these compounds?
CAS 89030-95-5 identifies GHK-Cu, CAS 137525-51-0 identifies BPC-157, and CAS 885340-08-9 identifies TB-500. Researchers can cross-check these numbers, along with each molecular formula, against an independent database such as PubChem to confirm chemical identity before use.
Does the pen kit format affect the research application?
The pen kit is a delivery/packaging format only. This listing makes no dosing, administration, or reconstitution recommendations; researchers determine their own protocols in line with their institution's research and safety governance.
How should Glow Skin 112mg be stored before use?
Store according to the conditions printed on the batch documentation and product label, generally in cool, dry, dark conditions consistent with lyophilized peptide storage. Exact storage parameters and shelf life are batch-specific and confirmed on the accompanying documentation.
Can this product be used in human or veterinary applications, or applied cosmetically?
No. It is sold strictly for laboratory and in-vitro research use. It is not a cosmetic or medicinal product, is not for human or veterinary use or application, is not licensed under the Human Medicines Regulations 2012, and has not been assessed by the MHRA for safety or efficacy under this listing.
Where can I buy Glow Skin for research use?
It is available for sale directly from Synedica UK, supplied with batch documentation and third-party testing for verified UK research buyers.
Related Reading
Author: Synedica UK Science & QA Team
Last updated: 29 August 2026